Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics

ByMike Hollan

June 25th 2026

The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels

ByNicholas Jacobus

June 25th 2026

Utilizing 100-Percent Domestic Additive Manufacturing: Q&A with Kyle Smith

ByMike Hollan,Kyle Smith

June 25th 2026

The FDA's approval of sacituzumab govitecan-hziy for first-line metastatic triple-negative breast cancer marks the first new backbone therapy option for this aggressive disease in more than two decades. Credit: Stock.Adobe.com/Sebastian Kaulitzki.

FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

ByPharmExec Staff

June 25th 2026

Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration

ByMike Hollan

June 24th 2026

Market Research 101

Articles in this issue

Related Content

Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics

The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels

Utilizing 100-Percent Domestic Additive Manufacturing: Q&A with Kyle Smith

FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration

Trending on PharmExec

The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026

Eli Lilly and Abbisko Announce Drug Development Collaboration

Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration

How 3D Printing Speeds Up Drug Production

FDA Pilot Targets Faster Early-Stage Drug Trial Starts